利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.023 秒)

    USES OF DC-SIGN AND DC-SIGNR FOR INHIBITING HEPATITIS C VIRUS INFECTION
    2.
    发明授权
    USES OF DC-SIGN AND DC-SIGNR FOR INHIBITING HEPATITIS C VIRUS INFECTION 有权
    DC-SIGN和DC SIGNR用于抑制流感病毒感染丙肝USE

    公开(公告)号：EP1411980B1

    公开(公告)日：2008-01-09

    申请号：EP02759107.2

    申请日：2002-06-26

    申请人： PROGENICS PHARMACEUTICALS, INC.

    发明人： OLSON, William, C. ,  MADDON, Paul, J.

    IPC分类号： A61K39/29 ,  C12N1/18 ,  G01N33/53

    CPC分类号： C07K14/005 ,  A61K2039/505 ,  C07K14/70525 ,  C07K16/1081 ,  C07K16/2851 ,  C12N2770/24222 ,  G01N33/576 ,  G01N33/5767

    摘要： This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. This infection provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGNR protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. Compounds of the present invention inhibit HCV infection of cells susceptible to HCV infection. The compounds of the present invention preferably have specificity for preventing or inhibiting infection by HCV and do not inhibit infection by other viruses, such as HIV, that may utilize DC-SIGN or DC-SIGNR for infection. Moreover the compounds of the present invention preferably do not interfere or inhibit members of the immunoglobulin superfamily, in particular, the compounds do not interfere with ICAM-2 or ICAM-3 or with ICAM-2-ilke, or ICAM-3-like molecules.

    CARBOHYDRATE VACCINES FOR VIRAL DISEASES
    4.
    发明公开
    CARBOHYDRATE VACCINES FOR VIRAL DISEASES 审中-公开
    碳水化合物疫苗抗病毒病

    公开(公告)号：EP1117432A1

    公开(公告)日：2001-07-25

    申请号：EP99950134.9

    申请日：1999-10-01

    申请人： PROGENICS PHARMACEUTICALS, INC.

    发明人： MADDON, Paul, J. ,  OLSON, William, C.

    IPC分类号： A61K39/21

    CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/6081 ,  C12N2740/16034

    摘要： This invention provides a method for treating or preventing a viral disease in a subject comprising administering to the subject an effective amount of a cellular carbohydrate antigen that is overexpressed during the viral disease, or a molecular mimic thereof, the amount of such carbohydrate or such mimic being effective to treat or prevent the viral disease. This invention also provides a vaccine for treating or preventing a viral disease comprising a cellular carbohydrate antigen that is overexpressed during the viral disease, or a molecular mimic thereof, the amount of such carbohydrate or such mimic being effective to treat or prevent the viral disease, and a pharmaceutically acceptable carrier.

    COMPOSITIONS AND METHODS FOR INHIBITION OF HIV-1 INFECTION
    7.
    发明公开
    COMPOSITIONS AND METHODS FOR INHIBITION OF HIV-1 INFECTION 审中-公开
    组合物和方法抑制HIV-1感染

    公开(公告)号：EP1322332A2

    公开(公告)日：2003-07-02

    申请号：EP01970984.9

    申请日：2001-09-14

    申请人： PROGENICS PHARMACEUTICALS, INC.

    发明人： OLSON, William, C. ,  MADDON, Paul, J.

    IPC分类号： A61K39/395 ,  G01N33/542 ,  C12Q1/70 ,  C07K16/00

    CPC分类号： C07K16/2866 ,  A61K38/16 ,  A61K39/39541 ,  A61K45/06 ,  A61K2300/00

    摘要： This invention provides a composition which comprises an admixture of three compounds, wherein: a) one compound is an antibody which binds to a CCR5 receptor; b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell; and c) one compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate; wherein the relative mass ratio of any two of the compounds in the admixture ranges form about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ CELL. This invention also provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of the subject invention effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.